Alecensa 150mg
Acquaintance with Alcitinib or Alcensa in the treatment of metastatic lung cancer
Alectinib is an oral chemotherapy drug used for non-small cell lung cancer, metastatic lung cancer, and is manufactured by Hoffmann-La Roche in Japan. Its brand name is Alecensa and it is part of the group of targeted cancer drugs, Target therapy. Its generic version has not yet been developed and is available to patients under the brand name Alcensa.
Alectinib, a drug for the treatment of malignant lung cancer
Alcitinib was approved by the FDA in December 2015 and by the European Medicines Agency in February 2017.
Alsensa belongs to tyrosine kinase inhibitors and is used to treat patients with non-small cell lung cancer, which has spread to the rest of the body and are ALK positive, in this case the cancer cells may spread to the bones, walls metastasize to the heart, abdomen and liver.
ALK is a gene that, when disrupted, causes non-small cell lung cancer or metastatic lung cancer.
Samples of the company's products
